Valneva (VALN)
(Delayed Data from NSDQ)
$7.76 USD
+0.18 (2.33%)
Updated Apr 22, 2024 09:50 AM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
VALN 7.76 +0.18(2.33%)
Will VALN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VALN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VALN
Strength Seen in Valneva SE Sponsored ADR (VALN): Can Its 15.8% Jump Turn into More Strength?
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why
VALN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why
What Makes Valneva SE Sponsored ADR (VALN) a New Buy Stock
Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab
Other News for VALN
Buy Rating on Valneva Supported by Promising Vaccine Developments and Solid Revenue Projections
Valneva SE Files Key Financial Documents for 2023
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
Valneva Highlights Vaccine Advances at World Congress